Progress in Influence Factors on Drug Induced Liver Injury
GU Li-wei1, ZHU Qing2, LI Xiao-dong1, RAN Qing-sen1, SHEN Jian-ying1*
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; 2.Institute of Pharmaceutical Research, Beijing Kawin Technology Share-Holding Co., Ltd., Beijing 100176, China
Abstract��Drug-induced liver injury (DILI) is a hot topic for clinicians, academia, drug companies and regulators. It is essential to understand risk factors of idiosyncratic DILI in order to accurately predict and prevent this problem. However, the role of factors on the pathogenesis of DILI is poorly understood. Indeed,both drug properties and host factors are likely interact at multiple levels to determine individual risks and clinical outcome of DILI. In this review, cross-disciplinary view over drug characteristics associated with hepatotoxicity is provided, and various host factors influencing individuals�� DILI risks at updating the current knowledge to stimulate future investigation are discussed.
REUBEN A, KOCH D G, LEE W M. Drug-induced acute liver failure:results of a US multicenter, prospective study [J]. Hepatology, 2010, 52(6):2065-2076.
[2]
TESCHKE R, ZHANG L, LONG H, et al. Traditional Chinese medicine and herbal hepatotoxicity:A tabular compilation of reported cases [J]. Ann Hepatol, 2015, 14(1):7-19.
[3]
ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21,789 patients [J]. Eur J Gastroenterol Hepatol, 2013, 25(7):825-829.
[4]
AMACHER D E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs [J]. Regul Toxicol Pharmacol, 1998, 27(2):119-130.
[5]
CHEN M, ZHANG J, WANG Y, et al. The liver toxicity knowledge base:A systems approach to a complex end point [J]. Clin Pharmacol Ther, 2013, 93(5):409-412.
[6]
BJORNSSON E S, BERGMANN O M, BJORNSSON H K, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland [J]. Gastroenterology, 2013, 144(7):1419-1425.
[7]
FONTANA R J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives [J]. Gastroenterology, 2014, 146(4):914-928.
[8]
CHALASANI N P, HAYASHI P H, BONKOVSKY H L, et al. ACG Clinical guideline:the diagnosis and management of idiosyncratic drug-induced liver injury [J]. Am J Gastroenterol, 2014, 109(7):950-966.
[9]
GULMEZ S E, LARREY D, PAGEAUX G P, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen):the multinational case-population SALT study [J]. Drug Saf, 2013, 36(2):135-144.
[10]
CHEN M, BORLAK J, TONG W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury [J]. Hepatology, 2013, 58(1):388-396.
[11]
KAPLOWITZ N. Avoiding idiosyncratic DILI:two is better than one [J]. Hepatology, 2013, 58(1):15-17.
[12]
UETRECHT J P. New concepts in immunology relevant to idiosyncratic drug reactions:the "danger hypothesis" and innate immune system [J]. Chem Res Toxicol, 1999, 12(5):387-395.
[13]
STEPAN A F, WALKER D P, BAUMAN J, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity:a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States [J]. Chem Res Toxicol, 2011, 24(9):1345-410.
[14]
STEPHENS C, ANDRADE R J, LUCENA M I. Mechanisms of drug-induced liver injury [J]. Curr Opin Allergy Clin Immunol, 2014, 14(4):286-292.
[15]
WILL Y, DYKENS J. Mitochondrial toxicity assessment in industry--a decade of technology development and insight [J]. Expert Opin Drug Metab Toxicol, 2014, 10(8):1061-1067.
[16]
CHEN M, BISGIN H, TONG L, et al. Toward predictive models for drug-induced liver injury in humans:are we there yet? [J]. Biomark Med, 2014, 8(2):201-213.
[17]
PARK B K, LAVERTY H, SRIVASTAVA A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity [J]. Chem Biol Interact, 2011, 192(1-2):30-36.
[18]
OBACH R S, KALGUTKAR A S, SOGLIA J R, et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose [J]. Chem Res Toxicol, 2008, 21(9):1814-1822.
[19]
PARK B K, BOOBIS A, CLARKE S, et al. Managing the challenge of chemically reactive metabolites in drug development [J]. Nat Rev Drug Discov, 2011, 10(4):292-306.
[20]
LUCENA M I, ANDRADE R J, RODRIGO L, et al. Trovafloxacin-induced acute hepatitis [J]. Clin Infect Dis, 2000, 30(2):400-401.
[21]
JAESCHKE H, MCGILL M R, RAMACHANDRAN A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury:lessons learned from acetaminophen hepatotoxicity [J]. Drug Metab Rev, 2012, 44(1):88-106.
[22]
MORGAN R E, TRAUNER M, VAN STADEN C J, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development [J]. Toxicol Sci, 2010, 118(2):485-500.
[23]
ALEO M D, LUO Y, SWISS R, et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump [J]. Hepatology, 2014, 60(3):1015-1022.
[24]
KOCK K, FERSLEW B C, NETTERBERG I, et al. Risk factors for development of cholestatic drug-induced liver injury:inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4 [J]. Drug Metab Dispos, 2014, 42(4):665-674.
[25]
FOUNTAIN F F, TOLLEY E, CHRISMAN C R, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection:a 7-year evaluation from a public health tuberculosis clinic [J]. Chest, 2005, 128(1):116-123.
[26]
LUCENA M I, ANDRADE R J, KAPLOWITZ N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury:the influence of age and sex [J]. Hepatology, 2009, 49(6):2001-2009.
[27]
CHALASANI N, FONTANA R J, BONKOVSKY H L, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States [J]. Gastroenterology, 2008, 135(6):1924-1934.
[28]
EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS W E. Pharmacogenomics and individualized drug therapy [J]. Annu Rev Med, 2006, 57:119-137.
[29]
OSTERREICHER C H, SCHULTHEISS J, WEHLER M, et al. Genetic polymorphisms of manganese-superoxide dismutase and glutathione-S-transferase in chronic alcoholic pancreatitis [J]. Mutagenesis, 2007, 22(5):305-310.
[30]
NG C S, HASNAT A, AL MARUF A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group [J]. Eur J Clin Pharmacol, 2014, 70(9):1079-1086.
[31]
HUNT C M, WESTERKAM W R, STAVE G M. Effect of age and gender on the activity of human hepatic CYP3A [J]. Biochem Pharmacol, 1992, 44(2):275-283.
[32]
ZIMMERMAN H J, MADDREY W C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol:analysis of instances of therapeutic misadventure [J]. Hepatology, 1995, 22(3):767-773.
[33]
YU K, GENG X, CHEN M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury [J]. Drug Metab Dispos, 2014, 42(4):744-750.
[34]
LUCENA M I, GARCIA-MARTIN E, ANDRADE R J, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury [J]. Hepatology, 2010, 52(1):303-312.
[35]
FROMENTY B. Drug-induced liver injury in obesity [J]. J Hepatol, 2013, 58(4):824-826.
[36]
PAULI-MAGNUS C, MEIER P J. Hepatobiliary transporters and drug-induced cholestasis [J]. Hepatology, 2006, 44(4):778-787.
[37]
DALY A K, DONALDSON P T, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nat Genet, 2009, 41(7):816-819.
[38]
CHO J, KIM L, LI Z, et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice:suggested roles for Tregs, estrogen, and IL-6 [J]. PLoS One, 2013, 8(4):e61186.
[39]
TOYODA Y, MIYASHITA T, ENDO S, et al. Estradiol and progesterone modulate halothane-induced liver injury in mice [J]. Toxicol Lett, 2011, 204(1):17-24.
[40]
FONTANA R J, HAYASHI P H, GU J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset [J]. Gastroenterology, 2014, 147(1):96-108.
[41]
DENG X, STACHLEWITZ R F, LIGUORI M J, et al. Modest inflammation enhances diclofenac hepatotoxicity in rats:role of neutrophils and bacterial translocation [J]. J Pharmacol Exp Ther, 2006, 319(3):1191-1199.
[42]
NGUYEN G C, SAM J, THULUVATH P J. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States:a nationwide analysis [J]. Hepatology, 2008, 48(4):1336-1341.
[43]
LOMTADZE N, KUPREISHVILI L, SALAKAIA A, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis [J]. PLoS One, 2013, 8(12):e83892.
[44]
SHUKLA V, CUENIN C, DUBEY N, et al. Loss of histone acetyltransferase cofactor transformation/transcription domain-associated protein impairs liver regeneration after toxic injury [J]. Hepatology, 2011, 53(3):954-963.
[45]
MURATA K, HAMADA M, SUGIMOTO K, et al. A novel mechanism for drug-induced liver failure:inhibition of histone acetylation by hydralazine derivatives [J]. J Hepatol, 2007, 46(2):322-329.
[46]
POOYA S, BLAISE S, MORENO GARCIA M, et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-1alpha hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver [J]. J Hepatol, 2012, 57(2):344-351.
[47]
VILLANUEVA J A, ESFANDIARI F, WHITE M E, et al. S-adenosylmethionine attenuates oxidative liver injury in micropigs fed ethanol with a folate-deficient diet [J]. Alcohol Clin Exp Res, 2007, 31(11):1934-1943.
[48]
BROWN G R, PERSLEY K. Hepatitis A epidemic in the elderly [J]. South Med J, 2002, 95(8):826-833.
[49]
SUZUKI A, YUEN N, WALSH J, et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury [J]. Clin Gastroenterol Hepatol, 2009, 7(8):882-888.
[50]
JOG N R, CARICCHIO R. Differential regulation of cell death programs in males and females by Poly (ADP-Ribose) Polymerase-1 and 17beta estradiol [J]. Cell Death Dis, 2013, 4:e758.
2016, Vol. 51 
